Table 1. Subject characteristics at... | American Society of Hematology

Table 1.

Subject characteristics at study entry

Cohort	Subject^*	Age (y)	CD4+ Count^† (cells/μL)	HIV-1 RNA^‡ (log₁₀ copies/mL)	HIV-1 DNA^1-153 (log₁₀ copies/ 10⁵cells)	Antiretroviral therapy^1-155
1	610 219	36	499	4.06	3.00	None
	620 733	48	943	4.08	2.52	None
	620 745	37	798	3.66	1.99	None
	61 145	58	495	<1.70	1.44	None
	61 146	58	1270	<1.70	<0.9	None
	610 354	31	884	3.00	2.14	None
	Median	43	841	3.33	2.07	—
2	610 051	38	338	2.70	2.78	ZDV/3TC/IDV
	620 495	38	230	<1.70	3.40	ZDV/3TC/IDV
	620 738	45	321	3.05	2.69	DDI
	61 149	49	368	3.51	1.36	None
	61 147	43	307	3.72	2.41	ZDV/3TC/SQV
	610 020	38	278	<1.70	2.69	ZDV/3TC/IDV
	Median	41	314	2.88	2.69	—
3	61 144	40	9	5.73	4.75	DEL/SQV/RTV
	620 743	42	33	4.06	3.63	ZDV/3TC/SQV
	61 148	34	150	4.18	3.04	ZDV/3TC/SQV
	620 736	53	162	<2.60	2.97	ZDV/3TC/IDV
	61 150	48	153	<1.70	2.91	D4T/3TC/SQV
	61 821	33	154	3.89	2.63	DDI/D4T/SQV
	Median	41	152	3.98	3.00	—

Cohort	Subject^*	Age (y)	CD4+ Count^† (cells/μL)	HIV-1 RNA^‡ (log₁₀ copies/mL)	HIV-1 DNA^1-153 (log₁₀ copies/ 10⁵cells)	Antiretroviral therapy^1-155
1	610 219	36	499	4.06	3.00	None
	620 733	48	943	4.08	2.52	None
	620 745	37	798	3.66	1.99	None
	61 145	58	495	<1.70	1.44	None
	61 146	58	1270	<1.70	<0.9	None
	610 354	31	884	3.00	2.14	None
	Median	43	841	3.33	2.07	—
2	610 051	38	338	2.70	2.78	ZDV/3TC/IDV
	620 495	38	230	<1.70	3.40	ZDV/3TC/IDV
	620 738	45	321	3.05	2.69	DDI
	61 149	49	368	3.51	1.36	None
	61 147	43	307	3.72	2.41	ZDV/3TC/SQV
	610 020	38	278	<1.70	2.69	ZDV/3TC/IDV
	Median	41	314	2.88	2.69	—
3	61 144	40	9	5.73	4.75	DEL/SQV/RTV
	620 743	42	33	4.06	3.63	ZDV/3TC/SQV
	61 148	34	150	4.18	3.04	ZDV/3TC/SQV
	620 736	53	162	<2.60	2.97	ZDV/3TC/IDV
	61 150	48	153	<1.70	2.91	D4T/3TC/SQV
	61 821	33	154	3.89	2.63	DDI/D4T/SQV
	Median	41	152	3.98	3.00	—

ZDV, zidovudine; 3TC, lamivudine; IDV, indinavir; DDI, didanosine; SQV, saquinavir; DEL, delavirdine; RTV, ritonavir.

All subjects were male.

†

Baseline values for CD4+ lymphocyte counts are averages of values obtained on days −3 and 0.

‡

Baseline plasma HIV-1 RNA values are the average of log₁₀ values obtained on days −3 and 0 for all subjects except subject 620 733, for whom the baseline value is from a single determination on day −18.

F1-153

Baseline copies HIV-1 DNA per 10⁵ CD4+ lymphocytes are averages of log₁₀ values obtained on days −3 and 0 for all subjects.

F1-155

Antiretroviral treatment regimen for days −60 through 27.

View Large

This Feature Is Available To Subscribers Only